Table 5.

Association between clinical response, T cell response and HLA/melanoma antigen expression by the original tumor

Patient #	Clinical response	T cell responsea	Percentage of cell expressingb
			MART1	Gp100	HLA-I
003	PRO	−	90	20	100
007c	SD	+	100	100	80
008c	SD	+	40	0	100
010c	SD	−	60	60	100
011c	PRO	−	< 5	< 5	< 5
012	SD	−	50	80	10
013	DF	+	30	5	70
014c	SD	+	100	100	100
016c	SD	+	40	90	100
017	PRO	−	60	10	100
022c	SD	ND	90	20	100
023	SD	+	ND	ND	ND
026	PRO	ND	100	100	100
028c	PRO	+	70	100	20
029c	PRO	−	100	100	0
031c	SD	+	100	60	100

^aOnly HLA class I-restricted T cell responses were considered, including those directed against autologous and/or allogeneic melanoma cells (see Table 4)

^bAs evaluated by immunohistochemistry

^cCorrelation between clinical response and HLA/MAA expression